|
|
|
| The value of the sFlt-1∶PlGF ratioin predictionin women with suspected preeclampsia |
| KE Weilin, ZHAO Weihua, LIN Qing |
| Department of Obstetrics, Shenzhen Second People’s Hospital, Shenzhen 518035, P.R.China |
|
|
|
|
Abstract Objective To investigate the predictive value of soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) ratio in women with suspected preeclampsia. Methods We performed a prospective, multicenter, observational study to prove in the short term in women with singleton pregnancies,whether low sFlt-1∶PlGF ratios (at or below a derived cutoff) predict the absence of preeclampsia within 1 week and whether high ratios (above the cutoff) predict the presence of preeclampsia within 4 weeks. Results In a subsequent validation study among an additional 550 women, an sFlt-1∶PlGF ratio of 38 or lower had a negative predictive value (i.e., no preeclampsia in the subsequent week) of 99.3% (95% confidence interval [CI], 97.9 to 99.9), with 80.0% sensitivity (95% CI, 51.9 to 95.7) and 78.3% specificity (95% CI, 74.6 to 81.7). The positive predictive value of an sFlt-1∶PlGF ratio above 38 for a diagnosis of preeclampsia within 4 weeks was 36.7% (95% CI, 28.4 to 45.7), with 66.2% sensitivity (95% CI, 54.0 to 77.0) and 83.1% specificity (95% CI, 79.4 to 86.3). Conclusion An sFlt-1∶PlGF ratio of 38 or lower can be used to predict the short-term absence of preeclampsia in women in whom the syndrome is suspected clinically.
|
|
Received: 26 February 2019
|
|
|
|
|
|
[1] Ananth C V, Keyes K M, Wapner R J. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis[J]. BMJ, 2013,347:6564.
[2] Goldenberg R L, Culhane J F, Iams J D, et al. Epidemiology and causes of preterm birth[J]. Lancet, 2008,371(9606):75-84.
[3] Staff A C, Benton S J, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers[J]. Hypertension, 2013,61(5):932-942.
[4] Maynard S E, Min J Y, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia[J]. J Clin Invest, 2003,111(5):649-658.
[5] Karumanchi S A, Epstein F H. Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? [J]. Kidney Int, 2007,71(10):959-961.
[6] Levine R J, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia[J]. N Engl J Med, 2006,355(10): 992-1005.
[7] Zhang J, Klebanoff M A, Roberts J M. Prediction of adverse outcomes by common definitions of hypertension in pregnancy[J]. ObstetGynecol, 2001,97(2):261-267.
[8] lvarez-Fernández I, Prieto B, Rodríguez V, et al. New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis[J].ClinChem Lab Med, 2014,52(8): 1159-1168.
[9] Chaiworapongsa T, Romero R, Korzeniewski S J, et al. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study[J]. J Matern Fetal Neonatal Med, 2014,27(2):132-144.
[10] Chappell L C, Duckworth S, Seed P T, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study[J]. Circulation, 2013,128(19): 2121-2131. |
| [1] |
. [J]. 滨州医学院学报, 2019, 42(2): 154-155. |
| [2] |
. [J]. 滨州医学院学报, 2019, 42(1): 58-59. |
|
|
|
|
